Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00455364
Status:
TERMINATED
Last Update Posted:
2013-02-06
First Post:
2007-04-02
Brief Title:
Voriconazole as Prophylactic Therapy in Lung Transplant Recipients
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
Assessment of Safety and Efficacy of Voriconazole as Prophylactic Antifungal Therapy for Lung Transplant Recipients
Status:
TERMINATED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Protocol never received funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VORI
Brief Summary:
The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation
Detailed Description:
All participants will receive itraconazole during their inpatient post transplant stay As an outpatient ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months All subjects will be followed in the clinic as per the standard transplant treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None